Alexander A. Fitzpatrick
CIK: 0001398595
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ARS Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 12, 2026SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct3.4K shares at avg. $10.00$34K - Jan 2, 2026SPRY
ARS Pharmaceuticals, Inc.
Award(A)DirectStock option (right to buy)
240K shares- - May 20, 2025SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct100K shares at avg. $5.58$558K - May 20, 2025SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct103K shares at avg. $14.10$1.5M - Jan 2, 2025SPRY
ARS Pharmaceuticals, Inc.
Award(A)DirectStock option (right to buy)
152.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 12, 2026 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 3,355 | $10.00 | $33,550 | Direct |
| Jan 2, 2026 | SPRY ARS Pharmaceuticals, Inc. | Award(A) Stock option (right to buy) | 240,000 | - | - | Direct |
| May 20, 2025 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 100,000 | $5.58 | $558,000 | Direct |
| May 20, 2025 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 102,969 | $14.10 | $1,451,513 | Direct |
| Jan 2, 2025 | SPRY ARS Pharmaceuticals, Inc. | Award(A) Stock option (right to buy) | 152,300 | - | - | Direct |
1-5 of 5 transactions
About Fitzpatrick Alexander A
Fitzpatrick Alexander A (SEC CIK 0001398595) files insider reports with the SEC as Chief Legal Officer of ARS Pharmaceuticals, Inc. (SPRY).
Signal8 holds 4 ownership filings by Fitzpatrick Alexander A, all Form 4s, filed between Jan 3, 2025 and Jun 12, 2026. Those filings report 5 transactions, from Jan 2, 2025 to Jun 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Fitzpatrick Alexander A's filings is in SAN DIEGO, CA.
Recent filings by Fitzpatrick Alexander A
- Jun 12, 2026: Open-market sale of SPRY shares (Form 4, code S).
- Jan 2, 2026: Grant or award of SPRY derivative securities (Form 4, code A).
- May 20, 2025: Option exercise of SPRY shares (Form 4, code M).
- May 20, 2025: Open-market sale of SPRY shares (Form 4, code S).
- Jan 2, 2025: Grant or award of SPRY derivative securities (Form 4, code A).
Other insiders filing for ARS Pharmaceuticals, Inc. (SPRY)
- Casale Donn, President and CEO
- Smith Margaret Ekins, Chief Commercial Officer
- RA CAPITAL MANAGEMENT, L.P., Director
- Dadoo Rajeev, Director
- Shah Pratik, Director
- Kelly Michael, Director